Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1705
http://purl.obolibrary.org/obo/NCIT_C1705
|
|---|---|
| Preferred Name | Tanomastat |
| Definitions |
A biphenyl matrix metalloproteinase (MMP) inhibitor (MMPI) with potential antineoplastic activity. Tanomastat inhibits MMP-2, MMP-3, and MMP-9, inhibiting extracellular matrix degradation and potentially inhibiting angiogenesis, tumor growth and invasion, and metastasis. MMPs consist of at least 18 zinc-containing endo-proteinases that are capable of degrading collagen and proteoglycan.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A biphenyl matrix metalloproteinase (MMP) inhibitor (MMPI) with potential antineoplastic activity. Tanomastat inhibits MMP-2, MMP-3, and MMP-9, inhibiting extracellular matrix degradation and potentially inhibiting angiogenesis, tumor growth and invasion, and metastasis. MMPs consist of at least 18 zinc-containing endo-proteinases that are capable of degrading collagen and proteoglycan. |
|---|---|
| prefLabel | Tanomastat
|
| label | Tanomastat
|
| PDQ_Closed_Trial_Search_ID | 42675
|
| code | C1705
|
| prefixIRI | NCIT:C1705
|
| in_subset | |
| Preferred_Name | Tanomastat
|
| FDA_UNII_Code | AM1ZX94EXH
|
| Contributing_Source | FDA
|
| Chemical_Formula | C23H19ClO3S
|
| Maps_To | Tanomastat
|
| CAS_Registry | 179545-77-8
|
| NCI_Drug_Dictionary_ID | 42675
|
| Legacy Concept Name | Tanomastat
|
| PubMedID_Primary_Reference | 16442153
|
| type | |
| ALT_DEFINITION | An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 42675
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0393069
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |